Zhejiang Orient Gene Biotech's (SHA:688298) subsidiaries received medical device registration certificates for three detection kits, according to a Shanghai Stock Exchange disclosure on Wednesday.
The devices are hepatitis B virus nucleic acid detection kit (fluorescence PCR method), and pepsinogen I and II detection kits (time-resolved fluorescence immunochromatography).
The certificate for hepatitis B kit is valid until Dec. 29, 2029, while those for the pepsinogen kits are valid until Dec. 23, 2029, the disclosure added.
Shares of the company closed over 3% lower.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.